# Erasca to Present at the Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-jefferies-global-healthcare-conference
Ticker: ERAS
Company: Erasca
Source: Erasca
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.erasca.com
## Summary

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies

## Article Body
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies
## Recent Company News
- 2026-06-25 13:46 EST — [Erasca to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-jefferies-global-healthcare-conference) — Source: Erasca
- 2026-06-25 13:46 EST — [Erasca Reports First Quarter 2026 Business Updates and Financial Results](https://biopharmsignal.com/news/ERAS/erasca-reports-first-quarter-2026-business-updates-and-financial-results) — Source: Erasca
- 2026-06-25 13:46 EST — [Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)](https://biopharmsignal.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-merck-to-evaluate-eras-0015-in-combination-with-keytrudar-pembrolizumab) — Source: Erasca
- 2026-06-25 13:46 EST — [Erasca Announces Pricing of Upsized Public Offering of Common Stock](https://biopharmsignal.com/news/ERAS/erasca-announces-pricing-of-upsized-public-offering-of-common-stock) — Source: Erasca
- 2026-06-25 13:46 EST — [Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ERAS/erasca-announces-closing-of-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares) — Source: Erasca
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)